Although ribosomes are ubiquitous and essential for life, recent data indicate that monogenic causes of ribosomal dysfunction can confer a remarkable degree of specificity in terms of human disease phenotype. Box C/D small nucleolar RNAs (snoRNAs) are evolutionarily conserved non-protein-coding RNAs involved in ribosome biogenesis. Here we show that biallelic mutations in the gene SNORD118, encoding the box C/D snoRNA U8, cause the cerebral microangiopathy leukoencephalopathy with calcifications and cysts (LCC), presenting at any age from early childhood to late adulthood. These mutations affect U8 expression, processing and protein binding and thus implicate U8 as essential in cerebral vascular homeostasis.
In 1996, Pierre Landrieu and colleagues described three unrelated children with a purely neurological disorder characterized by the radiological triad of cerebral white matter disease (leukoencephalopathy), intracranial calcifications and cysts (LCC) ( Fig. 1) 1 . This disease manifests as progressive cerebral degeneration, in which microangiopathy characterized by angiomatous-like blood vessels with gliosis and Rosenthal fiber deposition is the most striking pathological feature (Supplementary Fig. 1) [1] [2] [3] . The observation of sibling pairs, including affected females, suggested that LCC is a genetic disorder, likely inherited as an autosomal recessive trait. However, uncertainty has remained over the molecular basis of this phenotype, not least because of the wide range of age at presentation that has been observed 4 . Here we define LCC as an apparently single-gene disorder due to germline biallelic mutations in the gene encoding the box C/D snoRNA U8, thus indicating that LCC may represent a novel ribosomopathy. Furthermore, the genetic architecture of LCC illustrates some of the difficulties associated with the attribution of causation to sequence variants in non-protein-coding genomic DNA.
RESULTS

Identification of SNORD118 mutations in patients with LCC
Over a period of 12 years, we collected clinical data and biological samples relating to 40 patients affected with LCC ( Supplementary Table 1) . Surprisingly for a rare autosomal recessive disorder, there was a relative paucity of consanguineous families in our cohort (only 2 of 33 pedigrees), strongly suggesting that homozygous mutations might not typically be associated with this phenotype. These 40 patients, who were mainly of European ancestry, demonstrated an age at presentation ranging from early infancy to 54 years of age. In an attempt to define the genetic basis of LCC, we sequenced the exomes of 18 affected individuals and analyzed the data in the context of both an autosomal recessive trait and an autosomal dominant model with reduced penetrance. However, no candidate causal mutations were identified (data not shown). We then pursued a different strategy, using linkage and haplotype analysis in five pairs of affected siblings born to unrelated parents and two singletons who were the offspring of separate consanguineous unions. In this way, across the genome, we were able to identify a single region of >1 Mb in size with a Mutations in SNORD118 cause the cerebral microangiopathy leukoencephalopathy with calcifications and cysts 1 1 8 6 VOLUME 48 | NUMBER 10 | OCTOBER 2016 Nature GeNetics A r t i c l e s logarithm of odds (LOD) score >3. The minimal mapping locus of 1.2 Mb was located on chromosome 17 (genomic coordinates 7,721,931-8,930,080, GRCh37) (LOD score of 6.02), indicating that LCC diseasecausing variants lie within this interval (Supplementary Fig. 2) .
Considering the absence of any obvious pathogenic variants on reexamination of our sequence data covering the coding exons and essential splice sites in this mapping region, we undertook a capture sequencing assay of 3 Mb of genomic DNA on chromosome 17 (coordinates 7,000,000-10,000,000) using samples from ten unrelated patients. In each of these affected individuals, we identified two rare variants (defined as alleles with a frequency of <0.005 in the Exome Aggregation Consortium (ExAC) database) lying within a 199-bp stretch of DNA (8,076,761-8,076,960) encompassing the gene SNORD118 (NR_033294.1). Sanger sequencing confirmed these variants, leading us to analyze a further 30 patients demonstrating typical clinical and neuroradiological characteristics of LCC. In total, we observed two rare sequence variants that segregated with phenotypic status (40 affected individuals and 5 unaffected full siblings) in all 33 families in our cohort ( Fig. 2 , Table 1 and Supplementary Table 2 ). Where DNA was available (18 families), all parents showed appropriate heterozygosity for a single variant, except in two cases: in F819, the mother carried two rare variants, and her two affected children each inherited a distinct rare maternal allele in combination with a paternally derived genomic deletion of SNORD118 (Supplementary Fig. 3) ; and, in F906, a c.103G>A nucleotide alteration arose de novo on the paternal allele (with microsatellite analysis confirming paternity; Supplementary Table 3 ).
Of the total of 36 rare putative pathogenic variants observed in SNORD118, 13 were new (not annotated in the ExAC database, comprising more than 112,000 annotated alleles for each of these 12 variants, or our in-house data set of >5,000 exomes). In 15 and 16 of 33 families, the affected individuals were compound heterozygous for either one completely new allele and one rare allele or for two rare alleles (where the rarer of the two variants had an ExAC allele frequency of <0.00009756 in all cases), respectively. Consistent with our linkage analysis, two unrelated patients born to consanguineous parents demonstrated homozygosity for a rare allele (with allele frequencies of 0.0005781 and 0.00000887 for these putative mutations and no recorded homozygotes in the ExAC database). Further supporting the notion that biallelic variants in SNORD118 are causative of LCC, we noted recurrent putative mutant alleles in our cohort. Specifically, 11 new or rare variants were observed in more than one family, with a mutant allele shared by 4 or more different sets of families at 5 distinct nucleotide positions. One of these alleles, n.131C>G, was seen in four LCC families but was not recorded in the ExAC database of more than 112,000 alleles at this position, while an n.*5C>G variant, observed in the compoundheterozygous state in 8 disease pedigrees (8 of 66 alleles in affected individuals), had an ExAC frequency of 0.0005781 (1 in 1,730 control alleles) (8 in 66 versus 1 in 1,730; χ 2 test, P < 0.000005). Notably, screening of a panel of 677 European controls to determine the frequency of biallelic new or rare variants in the same person, which is not possible to derive from ExAC data, found only 4 individuals carrying two rare variants on distinct alleles (4 of 677 versus 20 of 20 LCC probands where it was possible to test for or impute biallelic inheritance; χ 2 test, P < 0.000005) (Supplementary Tables 4 and 5). Of further note, none of these alleles were new and only one was seen in our patient cohort. Thus, despite a remarkable variability in age at presentation for some patients, ranging from the neonatal period (for example, F172 and F344) to the sixth decade of life (for example, F433 and F1172), these data indicate that LCC is a genetically homogeneous disorder and that we have identified the disease-causing genomic variants in all 40 patients conforming to the LCC phenotype in our study.
Functional analysis of a selection of SNORD118 variants
SNORD118 encodes the box C/D snoRNA U8. Box C/D snoRNAs are evolutionarily conserved RNAs involved in ribosomal biogenesis and function 5 . The U8 snoRNA is independently transcribed, producing precursor U8 snoRNAs that are processed to mature box C/D U8 snoR-NAs 6 . The conserved box C/D motif binds to four core proteins, namely, 15.5K, NOP56, NOP58 and fibrillarin 7 . These proteins assemble onto the box C/D motif in a stepwise manner, with initial binding of 15.5K necessary for recruitment of the three remaining proteins, thus facilitating stabilization, processing and trafficking. U8 also contains a well-conserved LSm (like-Sm)-binding site 8 . Seven individual LSm proteins assemble into a ring structure that binds U8 to form a ribonucleoprotein complex. This U8 snoRNP is necessary for ribosomal RNA processing 9 .
Of the 36 mutations affecting U8 that we identified, one (c.-54_-49del) lies within a recognized 5′ enhancer element important for U8 expression 6 , 29 are within the U8 sequence and 4 are situated immediately 3′ to the U8 sequence in a region that is transcribed but then removed by processing of the precursor U8 transcript 10 . We also identified one complete gene deletion (in F819) and a further variant just 5′ to the start of the U8 sequence (F1424) of undetermined functional consequence. Within the mature U8 sequence itself, ten variants were observed in the box C/D and LSm-binding site, affecting nucleotides that are strictly conserved across evolution ( Supplementary Fig. 4) . Additionally, the variants at n.103, n.104 and n.113 lie within the stem of a hairpin loop that is very well conserved and would be predicted to decrease the stability of this structure ( Supplementary Fig. 5 ), while the three variants at n.81 and the variant at n.82 are situated within the highly conserved GAUU motif of the LSm-binding site.
To demonstrate a functional consequence for a selection of these U8 variants, we first generated a reporter construct encompassing the entire U8 promoter region, either with the wild-type sequence or the n.-54_-49del variant. In keeping with the promoter function of this region, we observed 109-fold higher reporter gene expression with the wild-type sequence in comparison to empty vector. In contrast, the n.-54_-49del variant was associated with a profound reduction in transcriptional activity relative to the wild-type sequence (Fig. 3) . 
npg
We then assessed the effect of four variants (n.57G>A, n.58A>G, n.61A>G and n.60_61insT) observed in the U8 box C region responsible for the interaction of U8 with the 15.5K protein. These patientassociated putatively causal mutations all resulted in reduced binding to the 15.5K protein in comparison to wild-type sequence ( Fig. 4) . Binding of His-tagged 15.5K to the n.57G>A and n.58A>G U8 was severely impaired ( Fig. 4a and Supplementary Fig. 6) , concordant with previous studies that demonstrated that disruption of the essential GA dinucleotide within the asymmetric internal loop completely abrogates 15.5K binding 11 . A more subtle reduction in 15.5K binding was seen with the n.61A>G and n.60_61insT variants ( Fig. 4a,b) . Binding of His-15.5K and n.61A>G demonstrated a shift in mobility at 100 nM of His-15.5K; however, this shift was less than that observed in wild-type RNA at the same concentration, and excess free RNA could be seen at all concentrations up to 500 nM, indicating that binding was impaired. Similarly binding of His-15.5K and n.60_61insT demonstrated a shift in mobility at 100 nM. This shift was less than that observed in wild-type RNA, and an equivalent shift was only achieved at the highest concentration tested (500 nM), indicating that binding was impaired. The nucleotides at positions n.60 and n.61 form part of the conserved stem loop II of the box C/D motif that is necessary for assembly of the box C/D snoRNP 12 .
Finally, to explore the effect of variants in the region immediately downstream of U8, including the n.*5C>G sequence alteration seen in eight families, we examined the in vitro processing of precursor U8 snoRNAs with extended 3′ regions encompassing four distinct variants. Previous work has defined a highly stereotyped pattern of processing of the SNORD118 transcript 10 , and we observed disturbed processing of the precursor U8 RNAs with the four mutations in comparison to wild-type RNA ( Fig. 5 and Supplementary  Fig. 7a ). Additionally, we examined in vitro processing of precursor U8 with the box C mutation n.58A>G located away from the extended 3′ region. The processing pattern observed for n.58A>G U8 was indistinguishable from that of wild-type U8 ( Supplementary Fig. 7b ), indicating that variants located in the 3′ extension of U8 specifically affect processing of the precursor U8 snoRNA.
Together, these data provide compelling evidence that the diseaseassociated variants that we identified are likely to have a functional effect on U8 activity.
LCC patient fibroblasts demonstrate a cellular phenotype
Although the clinical features of LCC are apparently limited to the central nervous system, we observed a marked reduction in expression of SNORD118 (U8) in patient-derived fibroblasts in comparison 8,075,000 8,095,000 8,115,000 8,135,000 8,155,000
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to control cells ( Fig. 6a) . Furthermore, primary fibroblasts from patients with LCC did not grow as well as cells from controls ( Fig. 6b) .
A higher percentage of LCC fibroblasts were senescent in comparison to control cells (Fig. 6c) , and a proliferation defect was confirmed by carboxyfluorescein succinimidyl ester (CFSE) labeling ( Fig. 6d,e ). This proliferative defect was not associated with increased incidence of apoptosis (Fig. 6f) , and we did not observe a disturbance in cell cycling under basal conditions or after treatment with the DNA crosslinking agent mitomycin C (Supplementary Fig. 8 ). Fibroblasts from patients with Coats plus also demonstrate proliferative defects (secondary to a problem with telomere homeostasis) 13, 14 , but qRT-PCR data for fibroblasts from a patient with Coats plus (F345) showed U8 levels comparable to those in controls. Because of an inability to grow enough cells, we were unable to investigate translation efficiency in fibroblasts. Epstein-Barr virus (EBV)-transformed patient-derived lymphoblasts, which grow normally (data not shown), did not demonstrate any abnormality in polyribosome (polysome) fractionation analysis ( Supplementary Fig. 9 ).
Although the phenotype of the exclusively neurological disease LCC is clearly distinctive, it is not pathognomonic, as a similar radiological association can also be seen in the context of the multisystem disorder Coats plus ( Supplementary Fig. 10 ) 15 . Coats plus is most frequently caused by mutations in CTC1, encoding conserved telomere maintenance component 1, but such mutations were not found in patients without systemic involvement, indicating that Coats plus and LCC are genetically distinct entities 13, 16 . Noting that SNORD118 is situated 50 kb upstream of CTC1 on chromosome 17p, we considered whether the LCC disease-associated variants across SNORD118 might be affecting a control element for the expression of CTC1. In the absence of a functional antibody against CTC1, expression was tested in patientderived fibroblasts using qRT-PCR and was similar to that in controls ( Supplementary Fig. 11 ). As expected, we observed increased DNA damage and numbers of telomere-dysfunction-induced foci (TIFs) in primary fibroblasts from patients with biallelic CTC1 hypomorphic mutations. In contrast, primary fibroblasts from patients with LCC displayed a similar number of DNA damage foci as controls and showed no evidence of disturbed telomeric integrity ( Supplementary  Fig. 12 ). We also looked at telomere length in four families using Flow-FISH, but we saw no consistent association with genotype status (data not shown). Taken in the context of the data relating to U8 per se, these results indicate that the physical proximity of SNORD118 and CTC1 is likely not causally relevant to LCC.
LCC fibroblasts do not demonstrate dysfunction of TMEM107
Finally, SNORD118 is located within the 3′ UTR of the proteincoding gene TMEM107 (NM_032354.3). Although dysfunction of TMEM107 could, in theory, be causal in the LCC phenotype, we did not observe any exonic variants in this gene. Moreover, A r t i c l e s expression of TMEM107 at the RNA and protein levels was similar for patients and controls in primary fibroblasts ( Supplementary  Fig. 13 ). An N-ethyl-N-nitrosourea (ENU)-mutagenesis-derived mouse with a homozygous loss-of-function mutation in Tmem107 demonstrates a defect in ciliogenesis leading to polydactyly, neural tube defects and microphthalmia-none of which are seen in patients with LCC 17 -and mutations in TMEM107 have been reported to result in a typical human ciliopathy phenotype 18 . These observations lead us to conclude that LCC is not consequent to TMEM107 dysfunction.
DISCUSSION
Here we demonstrate that mutations in SNORD118 cause the cerebral microangiopathy LCC. We identified completely new or rare biallelic sequence variants in all 40 radiologically stereotyped patients belonging to every one of the 33 families in our cohort. Moreover, the additional observation of sharing of new and rare alleles across multiple pedigrees and the results of screening of a large panel of control samples to determine the frequency of biallelic rare variants in unaffected individuals provide strong evidence of genetic causality. Of particular note, although LCC is rare and inherited as an autosomal recessive trait, only 2 of 33 mutation-positive families that we identified are consanguineous. In keeping with this finding, the affected individuals in 31 families were compound heterozygotes for two different SNORD118 variants, likely comprising one 'severe' and one 'mild' mutation. Nineteen families in our cohort carry one of six putative pathogenic variants with an overall allelic frequency of >0.001 in the ExAC control database (akin to, for example, the known pathogenic mutations p.Ala177Thr in RNASEH2B and p.Pro193Ala in ADAR1, which have allele frequencies of 0.001 and 0.002, respectively). In each of these 19 families, the second allele is either not present at all in ExAC (is completely novel; 9 families) or is only present at a very low frequency (<0.00009756; 1 in 10,250 alleles in all cases) ( Supplementary Table 6 ). We suggest that these more frequent, but still rare, variants are likely hypomorphic, whereas the still rarer variants confer a greater deleterious effect on U8. Similar to the situation observed in certain other Mendelian autosomal recessive diseases 13, 19, 20 , these data lead to the conclusion that biallelic null mutations in SNORD118 are likely incompatible with development, whereas homozygosity for (most) hypomorphic variants may be npg associated with no disease, later-onset pathology or a different phenotype not ascertained here. Such a possibility would explain the presence in the ExAC database of a small number of homozygotes for 5 of the 36 putatively causal mutations that we report (Supplementary Tables 2  and 6 ). Related to this understanding, it is of possible relevance that one, F446, of the two individuals in our cohort with homozygous SNORD118 mutations died at the youngest age of any of our patients (13 years), and we also note that two of our patients were completely asymptomatic until the sixth decade of life. Such variability in age at presentation likely relates to the overall functional effect of the two molecular lesions in combination. Furthermore, it is interesting that the mother in F819 carries two rare variants (on different alleles), both of which were seen in affected patients. However, she has not demonstrated any disease features to the age of 60 years. In contrast, both of her children, each carrying a different maternally derived rare allele in combination with a paternally inherited whole-gene deletion, experienced the onset of symptoms in their teenage years.
As the apparatus of protein synthesis, the ribosome is one of the most precisely constructed and regulated molecular machines in the cell 21 . The ribosome consists of rRNA and ribosomal proteins, with snoRNAs being an evolutionarily conserved group of non-proteincoding RNAs involved in the modification and processing of rRNAs. U8 is a vertebrate-specific factor, which is the only known snoRNA essential for maturation of the 60S large ribosomal subunit RNAs 5.8S and 28S (refs. [22] [23] [24] . It is thought that U8 snoRNA binds to newly transcribed pre-rRNA, thereby facilitating its proper folding, but later needs to be displaced for further processing to occur. We provide evidence that a variant in the promoter region of SNORD118 affects expression of the U8 snoRNA. Furthermore, alterations in box C disturb association of U8 with the snoRNA-binding protein 15.5K, while variants at the 3′ end of the gene confer aberrant processing of the precursor U8 snoRNA. In total, we recorded seven putatively causal mutations in the invariant box C/D motif, three within the stem of a hairpin loop that is very well conserved and would be predicted to decrease the stability of this structure and three within the highly conserved GAUU motif of the LSm-binding site. Taken together, these data indicate that the variants we describe are pathogenic and likely act as loss-of-function mutations.
LCC, which to our knowledge constitutes the first example of a human disease associated with point mutations in a gene encoding a box C/D snoRNA, illustrates some of the difficulties associated with the attribution of causation to sequence variants in a non-proteincoding portion of genomic DNA, where it is more challenging to use conventional in silico algorithms to assess the pathogenicity of sequence variants. This fact, together with the high degree of sequence variation across SNORD118 (Supplementary Table 7 ) and the finding that the disease occurs almost invariably in the context of compound heterozygosity, leads us to suggest that identification of the genetic basis of LCC would likely only have been possible with a large cohort of patients such as the one presented here. The degree of SNORD118 sequence variability in the general population is noteworthy, perhaps indicating that this variation confers important biological effects worthy of further study.
Alterations in ribosomal components, structure or function can cause a heterogeneous class of diseases referred to as the ribosomopathies 25 , with this diversity in clinical phenotype informing a developing understanding of the multiple specialized roles of the ribosome in normal physiology 26, 27 . Despite the U8 snoRNA being ubiquitously expressed, germline mutations in SNORD118 cause an exclusively neurological, progressive microangiopathy, thus suggesting further subtleties in ribosomal activity directly relevant to human health and disease. That being said, the precise link between U8 and cerebral vascular homeostasis awaits elucidation and may conceivably involve a direct effect on translation or other yet to be defined functions of U8.
ONLINE METHODS
Subject ascertainment. We ascertained subjects demonstrating a characteristic neuroradiological picture of white matter disease (leukoencephalopathy), intracranial calcification and brain cysts internationally through colleagues in pediatric neurology and clinical genetics. All subjects had previously been screened negative for mutations in CTC1. Written informed consent was obtained for all participants. The study had ethical approval from the Leeds Multicentre Research Ethics Committee (07/Q1206/7). Exome sequencing. Genomic DNA was extracted from lymphocytes from affected individuals by standard techniques. For whole-exome analysis, targeted enrichment and sequencing were performed on DNA extracted from peripheral blood from 18 patients: F281, F330, F331 (2 affected individuals), F343, F344, F362 (2 affected individuals), F426 (2 affected individuals), F433, F446, F454 (2 affected individuals), F521 (2 affected individuals), F551 and F564. Enrichment was undertaken using the SureSelect Human All Exon kits following the manufacturer's protocol (Agilent Technologies), and samples underwent paired-end sequencing on either an Illumina HiSeq 2000 or SOLiD platform. Sequence data were mapped using Burrows-Wheeler aligner (BWA) and the hg18 (NCBI36) human genome as a reference. Variants were called using SOAPsnp and SOAPindel (from the Short Oligonucleotide Analysis Package) with medium stringency. Access to exome data can be discussed by contacting the corresponding author.
Linkage analysis. We used the Merlin package 28 to perform nonparametric linkage analysis in five pairs of affected siblings (F331, F426, F454, F521 and F780) born to unrelated parents (with the inclusion of one unaffected sibling in F780) and two singletons (F344 and F446) who were the product of independent consanguineous unions (first-and second-cousin parents, respectively). We assumed allele frequencies as provided by Affymetrix for the European-ancestry population and calculated a LOD score using the Kong and Cox exponential model 29 . Data were annotated according to the hg19 human genome.
Genomic capture. Genomic capture, next-generation sequencing and bioinformatic analysis were performed as a service at BGI Tech (Hong Kong) on ten affected individuals from ten separate families (F330, F331, F362, F426, F433, F446, F454, F521, F691 and F780). A 3-Mb interval (chr. 17: 7,000,000-10,000,000) was captured using Agilent SureSelect technology and was then sequenced using the Illumina HiSeq 2000 platform. Genomes were aligned to the hg19 reference genome with BWA, and all subsequent analyses were performed with the hg19 genome.
Sanger sequencing. Mutation analysis was performed by direct sequencing of purified genomic PCR products using the BigDye Terminator v3.1 cycle sequencer system (Applied Biosystems) and an ABI 3130 DNA sequencer. Primers were designed for a 544-bp region around SNORD118. Primers used are listed in Supplementary Table 8 . Mutation description is based on the NR_033294.1 reference sequence for SNORD118.
Copy number analysis. Copy number analysis of SNORD118 in F819 was performed using DNA from the two affected individuals and their mother (paternal DNA not available). Parental samples from F426, F780 and F619 were used as controls. Copy number analysis was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) with 40 ng of DNA. The copy number probes chosen were Hs01424421_cn (76 bp upstream of U8) and Hs01021672_cn (72 bp downstream of U8). F619 Mum was chosen as the calibrator sample, and copy number was assessed with Applied Biosystems StepOne Software v2.1 and Applied Biosystems CopyCaller software V2.0.
Microsatellite genotyping.
To confirm maternity and paternity in F906, informative polymorphic microsatellite markers Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Amelogenin, Penta D, CSF1PO, D16S539, D7S820, D13S317 and D5S818 were genotyped using DNA from the affected child and the parents using the PowerPlex 16HS System (Promega).
Control panel sequencing.
Human Random Control DNA Panels (UK Caucasian blood donors) HCR-1 to HCR-5 were purchased from Public Health England. DNA panels NDPT099 and NDPT095 were acquired from the NINDS Human Genetics Resource Center DNA and Cell Line Repository. All panels were sequenced as above for the 544-bp region around SNORD118. Where two rare variants were identified, the PCR products were cloned into the pGEM-T Easy vector (Promega) so that each allele could be sequenced separately.
In silico analysis. In silico analysis of variants identified in patients with LCC was carried out using RNAfold (version 2.1.9), from the ViennaRNA suite.
U8 cloning.
A 525-bp region of chromosome 17 encompassing the entire U8 coding region was subcloned into the pGEM-T Easy vector. Site-directed mutagenesis was carried out using the QuikChange Site-Directed Mutagenesis protocol (Stratagene). Primers used for the cloning and site-directed mutagenesis are listed in Supplementary Table 6 .
In vitro transcription of U8 snoRNA. RNA was transcribed from PCR templates (primer sequences are listed in Supplementary Table 6 ) amplified from pGEM constructs containing wild-type or mutant U8 snoRNA sequence, using the T7 Ribomax Express Large-Scale RNA kit (Promega) in accordance with the manufacturer's instructions. Transcribed RNAs were purified on a 6% acrylamide/7 M urea gel. After passive elution from the gel, RNA was precipitated and resuspended in 20 µl of water. Quantification of RNA was carried out on the Boeco S-22 UV/Vis spectrophotometer.
Dephosphorylation and labeling of transcribed RNA. Dephosphorylation of transcribed RNA was carried out using 10 U of calf intestinal alkaline phosphatase (New England BioLabs) in Cut Smart buffer. Reactions were incubated for 1 h at 37 °C, followed by phenol extraction and resuspension in water to give a 1 µM final concentration. Dephosphorylated RNA (at 1 µM concentration) was end-labeled with 3,000 Ci/mmol [ 32 γ-P]ATP (Hartmann Analytic) using T4 polynucleotide kinase in PNK buffer (New England BioLabs). Labeled RNA was phenol extracted, precipitated and resuspended in water. The amount of labeled RNA was then determined using the Bioscan QC 2000 radioactivity counter.
15.5K cloning, expression and purification. The 15.5K ORF was amplified from human cDNA (see Supplementary Table 6 for primer sequences) and then cloned into the NdeI and XhoI sites of pET28a (Novagen) to produce the pET28a-TEV-15.5K plasmid. Positive clones were sequenced to confirm correct fusion of the human 15.5K ORF with the sequences encoding an N-terminal His 6 tag and TEV protease cleavage site. The pET28a-TEV-15.5K plasmid was transformed into Rosetta 2 (DE3) (Novagen), and expression of His 6 -TEV-15.5K was induced by using Overnight Express Instant TB medium (Novagen). His 6 -TEV-15.5K protein was purified as previously described for Snu13p 30 .
Electrophoretic mobility shift assays. For EMSAs, recombinant His-15.5K was incubated with 50,000 dpm 32 P-end-labeled U8 snoRNA in EMSA buffer (20 mM HEPES-KOH, 150 mM KCl, 1.5 mM MgCl 2 , 0.2 mM EDTA and 0.1% Triton X-100) for 30-45 min on ice. Resulting RNA-protein complexes were resolved on a native 7% acrylamide gel for 8.5 h at 4 °C. Gels were dried and exposed to X-ray film for approximately 8 h at −80 °C in the presence of an intensifying screen. Binding between His-15.5K and 32 P-end-labeled RNA was quantified using the Typhoon FLA 7000IP phosphorimager. For supershift assays, recombinant His-15.5K was incubated for 30 min on ice with 6×His antibody ab18184 (Abcam) before addition of 50,000 dpm 32 P-end-labeled U8 snoRNA. For the competition assays, recombinant His-15.5K was incubated for 30 min on ice with 2.5 µg of unlabeled U8 snoRNA before addition of 50,000 dpm 32 P-end-labeled U8 snoRNA.
3′-processing assays. For 3′-processing assays, 32 P-end-labeled U8 snoRNA was incubated with HeLa nuclear extract (CIL Biotech) at 30 °C in buffer containing 0.25 mM ATP, 10 mM phosphocreatine, 3.2 mM MgCl 2 , 20 mM HEPES KOH, pH 7.9, 2.6% PVA and 240 U RNasin (Promega). At 0 and 30 min, 10 µl of the reaction was removed and added to a tube containing 4 µl of stop solution (1 mg/ml proteinase K, 50 mM EDTA and 1% SDS). Reactions were then incubated at 37 °C for 15 min, phenol extracted, precipitated and resolved on a 6% acrylamide/7 M urea gel. Gels were dried and exposed to X-ray film overnight at −80 °C in the presence of an intensifying screen.
Luciferase assays.
A 298-bp region of chromosome 17 encompassing the entire U8 promoter region from control DNA was cloned into the pGEM-T Easy vector. Site-directed mutagenesis was carried out to create the n.-54_-49del mutation. DNA from wild-type and mutant clones was then subcloned into the pGL3 Basic vector (Promega). The primers used for the cloning are listed in Supplementary Table 6 .
HeLa-M cells were maintained in 75-cm 2 flasks in DMEM with GlutaMAX (Life Technologies, 10566-016) supplemented with 10% FBS (Sigma, F7524). Cells for transfection were plated out in triplicate wells in Corning 96-well clear-bottom plates at 1 × 10 4 cells per well in a 100-µl volume of culture medium. Transfections were carried out using the Effectene kit (Qiagen, 301425) according to the manufacturer's instructions. Cells in each well were cotransfected with 200 ng of pGL3 vector and 20 ng of pRL-TK control vector (10:1 ratio). Plates were incubated for 24 h at 37 °C in 5% CO 2 . Twenty-four hours after transfection, medium containing transfection reagent was removed from all wells and replaced with 75 µl of fresh culture medium. Cells were assayed for firefly and Renilla luciferase activity using the Dual-GLO Luciferase Assay System (Promega, E2920) in accordance with the manufacturer's instructions. Luciferase activity was measured on the BMG Labtech Fluostar Omega microplate reader. The firefly/Renilla luciferase ratio was calculated for each well after subtraction of average background values from untransfected cells. The mean firefly/Renilla ratio was calculated from triplicate values and used to calculate the fold increase in RLU as compared to empty pGL3 vector.
Polysome fractionation and profiling. Human lymphoblastoid cell lines (LCLs) from control (CTRL4) and patient (F433 and F446) samples were used for polysome profiling. Approximately 2 × 10 7 cells were incubated in RPMI medium with 100 µg/ml cycloheximide for 5 min at 37 °C in 5% CO 2 , followed by a wash in 1× PBS containing 100 µg/ml cycloheximide. Cells were collected by centrifugation at 200g for 5 min at 4 °C and resuspended in 425 µl of hypotonic buffer (5 mM Tris-HCl (pH7.5), 2.5 mM MgCl 2 , 1.5 mM KCl and 1× protease inhibitor cocktail, EDTA free). The resuspended cell mixture was supplemented with 5 µl of 10 mg/ml cycloheximide, 1 µl of 1M DTT and 100 U of RNasin. The cell mixture was incubated on ice for 10 min followed by 5 s of vortexing. The mixture was further supplemented with 25 µl of 10% Triton X-100 and 25 µl of 10% sodium deoxycholate and was vortexed again for 5 s. To pellet debris, the lysates were centrifuged at 16,000g for 7 min at 4 °C and the supernatant was transferred to a new prechilled tube. The optical density at 260 nm was measured for all lysates and adjusted so that all samples had the same optical density. Lysates were loaded onto sucrose gradients (15-50%) and centrifuged for 2.5 h at 274,000g. Polysome profiles were recorded using the Isco UA-6 UV/Vis detector.
Cell culture. Human primary fibroblasts and HeLa-M cells were cultured in DMEM (Gibco) supplemented with 10% heat-inactivated FCS and 1% penicillin-streptomycin. Human LCLs were cultured in RPMI supplemented with 10% heat-inactivated FCS and 1% penicillin-streptomycin. The control fibroblast line CTRL1 is a commercially available line purchased from the American Type Culture Collection. All other fibroblasts were generated by the referring institutes and shipped as growing cultures. All LCLs were generated as a service at St Mary's Hospital, Manchester. HeLa-M cells were a kind gift from the Manson laboratory at the University of Manchester. All cells are routinely tested for mycoplasma contamination. All putative patient cell lines were genotyped for relevant variants in SNORD118 to confirm authenticity.
Cell growth and proliferation. Proliferation was assessed for primary fibroblast cells from patients (F281, F334, F691 and F906) and healthy controls (CTRL1-CTRL3). Cells were plated in triplicate for each patient and control at 25 cells per well in a 96-well plate. Every cell from each well was counted under the microscope at 12 h after plating (day 0), and then at day 3 and day 6. Cell proliferation was measured in patient and healthy control primary fibroblasts using the Cell Trace CFSE Cell Proliferation kit (Life Technologies). Cells were labeled following the manufacturer's protocol and then plated as 5,000 cells per well in a 24-well plate. CFSE content was analyzed by flow cytometry at 30 min and 2 d after staining by flow cytometry on a Gallios flow cytometer with Kaluza acquisition software.
Apoptosis. Apoptosis was measured in patient and healthy control primary fibroblasts using an Annexin V-FITC kit (Beckman Coulter). Briefly, cells were seeded in 24-well plates and incubated for 24 h. Cells were collected, washed twice in PBS, and then stained with Annexin V-FITC and propidium iodide according to the manufacturer's instructions. The resulting fluorescence was detected by flow cytometry on a Gallios flow cytometer with Kaluza acquisition software.
Senescence. Senescence was measured in patient and healthy control primary fibroblasts using the Senescence β-Galactosidase Staining kit from Cell Signaling Technology. Briefly, cells were seeded in 24-well plates and incubated for 24 h. Cells were labeled following the manufacturer's instructions. The percentage of senescence was calculated with the following formula: (number of β-galactosidase-positive cells in five fields/total number of cells in these five fields) × 100.
DNA content. DNA content was measured in patient and healthy control primary fibroblasts. Briefly, cells were plated at 5,000 cells per well in 24-well plates and treated with 50 ng/ml mitomycin C (Sigma-Aldrich). Cells from a patient with Fanconi anemia were used as a positive control. After 5 d of treatment, cells were collected, washed twice in PBS and then incubated for 30 min in 70% ethanol. Cells were washed three times in PBS and incubated in PBS containing 1 µg/ml DAPI and 0.1% Triton X-100 (Sigma-Aldrich) for 30 min on ice; they were then analyzed by flow cytometry on a Gallios flow cytometer with Kaluza acquisition software.
ImmunoFISH for telomere-dysfunction-induced foci. Primary fibroblasts from healthy controls, CTC1-mutation-positive patients and patients with LCC were fixed for 5 min in 4% formaldehyde in water and permeabilized in PBS with 1% BSA and 0.1% Triton X-100. Cells were incubated with primary anti-53BP1 antibody (Santa Cruz Biotechnology) for 1 h at room temperature and then with Alexa Fluor 488-labeled secondary antibody (Life Technologies). Samples were fixed for 5 min in 4% paraformaldehyde and dehydrated in successive 5-min baths of 70% ethanol, 95% ethanol and 100% ethanol. PNA-Cy3-Telo-C probes (Dako) were hybridized according to the supplier's recommendations. Briefly, probes were incubated with the samples for 5 min at 80 °C and left in the dark at room temperature for 90 min. Samples were then washed twice in 70% formamide, 10 mM Tris-HCl and PBS and were mounted with DAPI mounting medium (Vectashield).
Protein analysis.
Whole-cell lysates were prepared from patient primary fibroblasts (5 × 10 6 cells per sample) using 10 mM EDTA/RIPA buffer containing protease inhibitors (Roche) and Halt phosphatase inhibitor (Thermo Scientific). For immunoblot analysis, 30 µg of total protein was loaded onto 15% SDS-PAGE gels, and electrophoresis was performed using the Mini-PROTEAN system (Bio-Rad Laboratories). Following wet-blotting transfer of protein onto nitrocellulose membrane (Li-Cor), non-specific antibody binding was blocked using Odyssey Blocking Buffer (PBS) for a minimum of 1 h at room temperature. Rabbit primary antibody to TMEM107 (Abcam, ab181396) was incubated with the membrane for 1 h at room temperature with agitation, using a 1:1,000 dilution in blocking buffer. As a loading control, membranes were incubated with a 1:3,000 dilution of mouse primary antibody to β-actin (Abcam, ab125248). Following washes with PBS, membranes were incubated with IRDye 800CW donkey anti-mouse IgG (Li-Cor, 925-32212) and IRDye 680RD donkey anti-rabbit IgG (Li-Cor, 925-68073) diluted 1:10,000 in blocking buffer for 45 min at room temperature. Following further washes, signal was detected using the Odyssey digital infrared imaging system (Li-Cor), and images were analyzed using Image Studio v5 (Li-Cor). 
